Assessing the Beneficial Effect of Lactobacillus Plantarum Ms1 and Lactobacillus Delbrueckii Yn1 on Colitis in a Rat Model Publisher



Varzeghan MH ; Zarrini G ; Sheikhzadeh FS ; Modarresi MH
Source: Iranian Journal of Microbiology Published:2025

Abstract

Background and Objectives: Probiotics are effective in improving inflammatory bowel disease (IBD). This study assessed the effect of mesalazine and two candidate probiotics on the improvement of acetic acid (AA)-induced colitis model. Materials and Methods: Lactobacillus plantarum MS1and Lactobacillus delbrueckii YN1 were used for IBD model in rat. Twenty-five male Wistar rats weighing 250 ± 50 grams were used in 5 classified groups: Control (CO); Colitis (CL); Colitis, Probiotic (CLP); Colitis, Mesalazine (CLM); Colitis, Probiotic, Mesalazine (CLPM) and the treatment period was 3 weeks. The rats were treated with mesalazine 30 mg/kg and probiotic 109 CFU/ml after induction of colitis. Histopathological and immunological analyses were performed to evaluate the effects of probiotic bacteria on IBD. Results: The results showed that the probiotic bacteria reduced inflammation (P<0.05), extent (P<0.01), crypt abscesses (P<0.01), edema (P<0.05), inflammatory cell infiltration (P<0.5), and increased mucosa (P<0.001) in rats. Mesalazine administration in animals with colitis did not have a significant effect. Administration of probiotics in both CLP and CLPM groups reduced extent, crypt abscesses, edema, and inflammatory cell infiltration and showed an important role in the down-regulation of consolidation of pro-inflammatory factors (TNFα, IL-6, and IL-17), as well as up-regulation of anti-inflammatory factors such as IL-10. Conclusion: Lactobacillus plantarum MS1 and Lactobacillus delbrueckii YN1 have shown significant potential in alleviating AA-induced colitis symptoms. Their administration leads to a marked reduction in pro-inflammatory cytokines such as TNF-α, IL-17, and IL-6, while enhancing IL-10 levels, indicating their promise as therapeutic candidates for inflammatory bowel disease (IBD). © 2025 Elsevier B.V., All rights reserved.